FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagehl7.fhir.us.mcode.r4
Resource TypeMedicationAdministration
IdMedicationAdministration-cancer-related-medication-admin-doxorubicin-jenny-m.json
FHIR VersionR4

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

Generated Narrative: MedicationAdministration cancer-related-medication-admin-doxorubicin-jenny-m

Normalization Basis Extension: Body weight characteristic (observable entity)

status: Completed

category: Outpatient

medication: 10 ML doxorubicin hydrochloride 2 MG/ML Injection

subject: Jenny M Female, DoB: 1965-01-01 ( Medical Record Number: MRN1234 (use: usual, ))

effective: 2018-04-22

Performers

-Actor
*Practitioner Nancy Nurse

reasonReference: Condition Primary malignant neoplasm of female left breast (disorder)

request: MedicationRequest: extension = Curative - procedure intent (qualifier value); status = active; intent = order; category = Outpatient; medication[x] = DOXOrubicin; authoredOn = 2018-04-12

note: doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects. (By Practitioner/us-core-practitioner-nancy-oncology-nurse @2018-04-22)

Dosages

-RouteDose
*Intravenous route (qualifier value)105.96 mg (Details: UCUM codemg = 'mg')

Source1

{
  "resourceType": "MedicationAdministration",
  "id": "cancer-related-medication-admin-doxorubicin-jenny-m",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-administration"
    ]
  },
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-normalization-basis",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "363804004",
            "display": "Body weight characteristic (observable entity)"
          }
        ]
      }
    }
  ],
  "status": "completed",
  "category": {
    "coding": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/medicationrequest-category",
        "code": "outpatient"
      }
    ]
  },
  "medicationCodeableConcept": {
    "coding": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code": "1790099",
        "display": "10 ML doxorubicin hydrochloride 2 MG/ML Injection"
      }
    ]
  },
  "subject": {
    "reference": "Patient/cancer-patient-jenny-m"
  },
  "effectiveDateTime": "2018-04-22",
  "performer": [
    {
      "actor": {
        "reference": "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      }
    }
  ],
  "reasonReference": [
    {
      "reference": "Condition/primary-cancer-condition-jenny-m"
    }
  ],
  "request": {
    "reference": "MedicationRequest/cancer-related-medication-request-doxorubicin-jenny-m"
  },
  "note": [
    {
      "authorReference": {
        "reference": "Practitioner/us-core-practitioner-nancy-oncology-nurse"
      },
      "time": "2018-04-22",
      "text": "doxorubicin (60 mg/m² IV), 105.96 mg in 50 ml 0.9% normal saline administered by continuous infusion. Patient tolerated infusion without side effects."
    }
  ],
  "dosage": {
    "route": {
      "coding": [
        {
          "system": "http://snomed.info/sct",
          "code": "47625008",
          "display": "Intravenous route (qualifier value)"
        }
      ]
    },
    "dose": {
      "value": 105.96,
      "unit": "mg",
      "system": "http://unitsofmeasure.org",
      "code": "mg"
    }
  }
}